
HHS Peptide Policy: 6 Peptides Pharmacies Can Compound for Now
There is finally a federal lane for six popular peptides. In a notice filed Oct 28, 2026 and scheduled for the Federal Register on Oct 30, HHS says it “does not intend to take enforcement action” against state-licensed pharmacies, federal facilities or licensed physicians compounding BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. That is real progress on access. It is not FDA approval, and it says nothing about whether these peptides work.
Key facts
- Oct 28, 2026: HHS filed its “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” signed by Secretary Robert F. Kennedy Jr., with publication set for Oct 30.
- 6 peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon, each limited to specific forms and routes.
- 10 conditions: AJMC counts 10, including a patient-specific prescription, one active ingredient per product and serious adverse event reporting to the FDA.
- Not approved: none of the six is FDA-approved or on the 503A Bulks List, and the FDA has not proposed adding them, per AJMC on Oct 29, 2026.
- Comments: open for 2 weeks after publication, which works out to about Nov 13, 2026 if the notice publishes as scheduled.
What did HHS actually change?
It changed who is likely to get in trouble, not what the FDA has approved. Enforcement discretion means an agency chooses not to act against something it could otherwise act on. HHS says the goal is “to expand and improve patient access” because of “significant interest” in these peptides and “the lack of availability of approved products.”
This is the document we were waiting on after the one-line White House filing on Oct 15. The list matches the July advisory vote, where the panel backed 6 of 7 peptides and rejected emideltide (DSIP).
Which forms are covered?
As summarized by AJMC and Drug Topics from the HHS appendix:
| Peptide | Form | Routes covered |
|---|---|---|
| BPC-157 | Acetate | Under the skin, into muscle, oral, topical |
| TB-500 | Acetate | Under the skin or into muscle |
| MOTS-c | Acetate | Under the skin or into muscle |
| Epitalon | Acetate | Under the skin or into muscle, in intermittent courses |
| KPV | Acetate | Topical or oral |
| Semax | Free base | Intranasal |
This table describes the policy’s scope. It is not guidance on how anyone should use these peptides. Drug Topics reports that IV use, injectable KPV and injectable Semax fall outside it. So do CJC-1295, ipamorelin, AOD-9604 and emideltide.
What do pharmacies have to do?
The conditions are the good part of this story, because they are built around the problems of the gray market:
- Traceable supply: the raw ingredient must come from an FDA-registered original manufacturer following good manufacturing practice. Registering a distributor or repacker is not enough, per Drug Topics.
- Testing: certificates of analysis must cover identity, purity, potency and contaminants such as endotoxins and heavy metals.
- One ingredient: each product can contain only one listed peptide, so a BPC-157 and TB-500 combination falls outside the policy.
- Real prescriptions: a patient-specific prescription is still required. Drug Topics says there is no office-stock or resale route for clinics.
- Safety reporting: serious adverse events and quality problems go to the FDA’s MedWatch program and to the relevant states.
- Labels and devices: products must be labeled as compounded and not for resale, and any co-packaged device must be an FDA 510(k)-cleared syringe.
- Oral products: compounders must document adequate absorption in humans for that specific formulation.
HHS frames this as a controlled alternative to research-use products from foreign manufacturers, according to AJMC. The gap is real: one physician told AJMC that gray-market peptides often contain 5% to 75% of the labeled amount.
The honest caveats
Access and proof are different things.
- Evidence is still thin. FDA briefing materials found the available studies, including 5 on BPC-157, were short, small and not enough to establish safety or effectiveness, per AJMC. FDA career scientists recommended against all 7 peptides reviewed in July. Our BPC-157 evidence review walks through the human data, and on the Peptiblox Score five of the six are graded D (mostly animal or lab data) and Semax is graded C.
- Compounded does not mean reviewed. In the notice’s own words, the FDA “does not review their safety, effectiveness, or quality before they are marketed.”
- Safety reports exist. AJMC reports 10 serious FDA adverse event reports tied to BPC-157 since 2021, 8 of them in 2026. Those reports do not prove the peptide caused the events.
- The wording is soft. The notice calls the policy a “draft” in its background section and says it “does not establish any rights for any person and is not binding on HHS or the public.”
- It can be pulled. HHS “may revisit” the policy if a safety signal or product quality issue appears. AJMC reports no fixed end date, with the policy lasting for each peptide until the FDA addresses it in a final rule, and says rulemaking can take 12 to 24 months.
- There is opposition. The Partnership for Safe Medicines petitioned the FDA to disregard the July vote, alleging that the panel was formed unlawfully and had conflicts of interest. Those are the group’s allegations, and the petition was unresolved as of AJMC’s Oct 29 report.
Does this make BPC-157 legal?
Closer, not settled. As of Oct 30, 2026, BPC-157 is still unapproved and still not on the 503A Bulks List. What is new is that HHS says it does not intend to enforce against compounders who meet the conditions. The policy does not stretch to 503B outsourcing facilities, explained in our 503A vs 503B guide.
States are a separate layer. Jeff Cohen of the American Peptide Association told Reuters, as quoted by AJMC, that states may not follow the federal move. Louisiana went the other way with Act 374, effective Aug 1, 2026, which bars licensing boards from prohibiting compliant peptide prescribing and compounding. Check the current status of each peptide on our legal status tracker.
What comes next
- About Nov 13, 2026: the comment window closes, assuming publication on Oct 30.
- February 2027: the FDA’s compounding panel was scheduled, as of July, to review five more unapproved peptides.
- No date set: the FDA still has to decide through rulemaking whether to add or exclude each of the six.
What it means for you
If one of these peptides is on your radar, the legit path now looks like any other compounded prescription: a licensed provider evaluates you, decides whether it makes sense, and sends a patient-specific prescription to a licensed compounding pharmacy that can meet these conditions. Expect to pay cash, since AJMC notes compounded drugs generally sit outside standard pharmacy coverage. The policy offers no promise of results. Bring your questions to a licensed provider, and read how peptides get prescribed so you know what a real process looks like.
Sources
- Federal Register public inspection: HHS Enforcement Discretion Policy notice, Doc. 2026-22192 (filed Oct 28, 2026; publication date Oct 30, 2026)
- AJMC: HHS draft policy eases enforcement on 6 compounded peptides (Oct 2026)
- AJMC: 5 things to know about HHS’s interim peptide compounding policy (Oct 29, 2026)
- Drug Topics: HHS lets pharmacies compound peptides as FDA writes official rule (Oct 29, 2026)
- NCPA: FDA grants enforcement discretion to compounding six peptides (Oct 29, 2026)
- Partnership for Safe Medicines: statement on the 503A peptide enforcement policy (Oct 28, 2026)
Educational content only, not medical advice or legal advice. Talk to a licensed provider about whether any medicine is right for you.